Evidence map›Paper›PMID 42891742›Full record

ReviewMolecular biology reports2026

Utilization of the CRISPR-Cas system for investigating tuberculosis drug resistance.

Yanhui Yuan, Jiahui Deng, Xiang Li, Xi Zheng, Yunhong Tan, Kun Xu

Abstract readReview
PubMed Publisher
In one paragraph

Review in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yanhui YuanSchool of Public Health, Hunan Normal University, Changsha, 410013, Hunan, PR China.
Jiahui DengSchool of Public Health, Hunan Normal University, Changsha, 410013, Hunan, PR China.
Xiang LiSchool of Public Health, Hunan Normal University, Changsha, 410013, Hunan, PR China.
Xi ZhengSchool of Public Health, Hunan Normal University, Changsha, 410013, Hunan, PR China.
Yunhong TanThe Hunan Chest Hospital, Changsha, 410013, Hunan, PR China. 1220163360@qq.com.
Kun XuSchool of Public Health, Hunan Normal University, Changsha, 410013, Hunan, PR China. xu_kun2022@163.com.ORCID http://orcid.org/0000-0002-2240-9873

Funding

he Science and Technology Program of Hunan Province 2026JK2006, 2026JJ80902, 2023JJ30430the Department of Education of Hunan Province 23A0075the National Natural Science Foundation of China 82574159, 82173572
6 · The paper itself

Abstract

Drug-resistant tuberculosis(TB) presents a significant challenge to global efforts to control the disease. Addressing this issue requires a comprehensive understanding of drug resistance in Mycobacterium tuberculosis (M.tb). The clustered regularly interspaced short palindromic repeat (CRISPR) and CRISPR-associated protein (Cas) system are efficient genome-editing tools for various organisms and have facilitated new research directions regarding drug resistance in M.tb. This review summarizes recent progress in applying CRISPR/Cas technology to investigate drug resistance mechanisms in M.tuberculosis and discusses the potential of the CRISPR/Cas system as an integrated platform to transform research paradigms and enhance understanding of M.tuberculosis drug resistance mechanisms.

Indexed as

CRISPR-Cas SystemsDrug Resistance, BacterialMycobacterium tuberculosisTuberculosis, Multidrug-ResistantAntitubercular AgentsClustered Regularly Interspaced Short Palindromic RepeatsGene EditingHumansAntitubercular AgentsCRISPR-Cas systemDrug resistanceMycobacterium tuberculosis

Identifiers

PMID42891742

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.